GH Research assumed with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage of GH Research (GHRS) with an Overweight rating and $25 price target Data generated for psychedelics across a number of mental health disorders have been “transformational,” and the unmet need is “enormous” and growing, the analyst tells investors in a research note. The firm says sees the psychedelic total addressable market ultimately reaching $50B per year, which would be roughly 1M-1.5M patients treated per year, still only modest penetration, and believes there is room for plenty of successful options and companies offering psilocybin and novel synthetic products.